Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2021.10.17.464755

PathoClock and PhysioClock in mice recapitulate human multimorbidity and heterogeneous aging

Salimi, S.·Pettan-Brewer, C.·Ladiges, W.
View original source ↗Export metadata ↓

Abstract

Multimorbidity is a public health concern and an essential component of aging and healthspan but understudied because investigative tools are lacking that can be translatable to capture similarities and differences of the aging process across species and variability between individuals and individual organs. To help address this need, body organ disease number (BODN) borrowed from human studies was applied to C57BL/6 (B6) and CB6F1 mouse strains at 8, 16, 24 and 32 months of age, as a measure of systems morbidity based on pathology lesions to develop a mouse PathoClock resembling clinically based Body Clock in humans, using Bayesian inference. A mouse PhysioClock was also developed based on measures of physiological domains including cardiovascular, neuromuscular, and cognitive function in the same two mouse strains so that alignment with BODN was predictable. The results revealed between- and within-age variabilities in PathoClock and PhysioClock, as well as between-strain variabilities. Both PathoClock and PhysioClock correlated with chronological age more strongly in CB6F1 than C57BL/6. Prediction models were then developed, designated as PathoAge and PhysioAge, using regression models of pathology and physiology measures on chronological age. PathoAge better predicted chronological age than PhysioAge as the predicted chronological and observed chronological age for PhysioAge were complex rather than linear. In conclusion, PathoClock and PhathoAge can be used to capture biological changes that predict BODN, a metric developed in human, and compare multimorbidity across species. These mouse clocks are potential translational tools that could be used in aging intervention studies.

Source connections

Explore related subjects

pathologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Salimi, S., Pettan-Brewer, C., Ladiges, W.. 2021-10-18. PathoClock and PhysioClock in mice recapitulate human multimorbidity and heterogeneous aging. https://doi.org/10.1101/2021.10.17.464755

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗
bioRxiv2026

Relative expression of THY1 and PDGFRA in equine endometrosis in relation to severity, histopathological features and endometrial transcripts

Equine endometrosis is a degenerative uterine disease characterized by periglandular fibrosis and represents a major cause of subfertility in mares. While stromal cell activation results in pathological tissue remodeling, the involvement of cell-surface integrators (THY1) and growth factor receptors (PDGFRA) was not researched. This study evaluated the relative mRNA expression of THY1 and PDGFRA across Kenney and Doig (KD) endometrosis categories and specific histopathological features. Additionally, transcriptomic correlation profiles between target genes and markers of myofibroblast differentiation (ACTA2), cellular proliferation (MKI67), and steroid hormone receptors (ESR1, PGR) were analyzed. Endometrial samples (n = 47) were quantified using RT-qPCR. Relative mRNA expression of THY1 differed significantly across KD categories (p = 0.014), exhibiting a transient upregulation in category IIA compared with category I (p = 0.009) and category IIB (p = 0.002). Furthermore, THY1 relative mRNA expression was significantly elevated in tissues with glandular basal lamina disruption (p = 0.022). Conversely, PDGFRA relative mRNA expression remained stable across disease categories (p > 0.05). THY1 relative mRNA expression correlated very strongly with ACTA2 ({rho} = 0.875, p < 0.001) and strongly with ESR1 ({rho} = 0.652, p < 0.001). PDGFRA relative mRNA expression exhibited a very strong positive correlation with ESR1 ({rho} = 0.864, p < 0.001) and a strong positive correlation with MKI67 ({rho} = 0.674, p < 0.001). These results indicate that THY1 transcription is transiently induced during early stromal remodeling and basal lamina loss, whereas PDGFRA maintains constitutive transcript stability. Observed co-expression profiles reflect statistical co-variation among stromal remodeling, proliferative, and steroid-responsive cell populations in bulk tissue.

pathology↗
bioRxiv2026

CD8+ T-cells protect against experimental atherosclerosis through antigen specific interactions in the plaque

Atherosclerosis is a chronic inflammatory disease with a significant adaptive immune component. CD8+ T cells accumulate in plaques and display signatures of antigen-specific activation. However, whether this accumulation is driven by local antigen recognition and what functional consequences follow, remains poorly understood. Here we address this gap of knowledge using loss- and gain-of-function experiments. Atherosclerotic Rag-/-Ldlr-/- mice received adoptively transferred wildtype or antigen-restricted CD8+ T cells alongside CD4+ T cells to distinguish antigen-specific from antigen-independent responses. In a complementary model, ApobOVA-TGxLdlr-/- mice, expressing an ovalbumin-tagged variant of the atherosclerosis-associated ApoB100 protein, enabled OT-I CD8+ T cells to function as atherosclerosis-antigen-specific CD8+ T cells. T-cell distribution, activation and phenotype were assessed systemically and within lesions, plaque burden and composition were quantified histologically. Wildtype CD8+ T cells accumulated significantly more in aortic lesions compared to antigen-restricted CD8+ T cells, and exhibited increased activation, exhaustion and cytokine secretion, indicating that plaque-infiltrating T cells are predominantly antigen-specific. Perturbing antigen-specific CD8+ T-cell interactions significantly decreased plaque stability index, suggesting a protective role for antigen-specific CD8+ T cells. In ApobOVA-TGxLdlr-/- mice, OT-I T cells accumulated at high frequency in the liver, consistent with hepatic ApoB100-expression, and were found in circulation and aorta. Histological analysis revealed reduced plaque burden in OT-I recipients, reproducing an atheroprotective effect of antigen-specific CD8+ T-cell responses. Plaque reduction coincided with reduced TUNEL, but similar Caspase 3 staining, suggesting OT-I transfer results in reduced secondary necrosis. In line with this, CD47 expression in OT-I recipient mice was reduced and in vitro, OT-I but not antigen non-specific CD8+ T cells reduced expression of CD47 on OVA-presenting foam cells. CD8+ T-cell accumulation in experimental atherosclerosis is driven primarily by antigen-specific interactions and such responses are associated with plaque stabilization and reduced lesion formation, potentially through induction of apoptosis and prevention of secondary necrosis

pathology↗